Elliot Wilbur
Stock Analyst at Raymond James
(1.91)
# 3,203
Out of 5,008 analysts
55
Total ratings
33.33%
Success rate
5.29%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $25 → $32 | $13.99 | +128.73% | 8 | May 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $91.68 | -9.47% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $60 → $40 | $40.99 | -2.42% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $10.60 | +211.32% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $21.68 | +98.34% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $3.33 | +3,503.60% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $10.14 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $20.07 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $142.77 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $20.45 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $7.55 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $25.83 | - | 3 | Nov 9, 2017 |
ADMA Biologics
May 8, 2025
Maintains: Strong Buy
Price Target: $25 → $32
Current: $13.99
Upside: +128.73%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $91.68
Upside: -9.47%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $60 → $40
Current: $40.99
Upside: -2.42%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $10.60
Upside: +211.32%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $21.68
Upside: +98.34%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $3.33
Upside: +3,503.60%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.14
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $20.07
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $142.77
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $20.45
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $7.55
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $25.83
Upside: -